Aminocaproic acid has received approval from the Food and Drug Administration (FDA) for the therapeutic management of acute hemorrhages caused by elevated fibrinolytic activity leading to surgical complications after cardiac surgery, hematological disorders, hepatic cirrhosis, and neoplastic disease.

Aminocaproic acid has been used off-label for the following indications:

- Prevention of dental bleeding after dental procedures in patients with hemophilia A

- Intracranial rebleeding prophylaxis after recent aneurysmal subarachnoid hemorrhage

- Prophylaxis of secondary ocular bleeding in the setting of traumatic hyphema

- Angioedema prophylaxis in patients with hereditary angioedema

- Surgical bleeding prophylaxis for a cardiopulmonary bypass as monotherapy or in combination with desmopressin